Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients

Korean Journal of Anesthesiology

Volumn 58, Issue 4, 2010, Pages 338-343

  Huh, Billy ^a   Park, Chan Hong ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Daegu Wooridul Hospital   (South Korea)

Author keywords

Methadone; Opioid; QT interval

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; METHADONE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG RESEARCH; DRUG USE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; QT PROLONGATION; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION;

EID: 77953379085     PISSN: 20056419     EISSN: 20057563     Source Type: Journal    
DOI: 10.4097/kjae.2010.58.4.338     Document Type: Article

References (24)

1. Effective medical treatment of opiate addiction. NIH Consens Statement Online 1997; 15: 1-38.
2. Decerf JA, Gressens B, Brohet C, Liolios A, Hantson P. Can methadone prolong the QT interval? Intensive Care Med 2004; 30: 1690-1691
3. Lamont P, Hunt SC. A twist on torsade: a prolonged QT interval on methadone. J Gen Intern Med 2006; 21: C9-12. (Pubitemid 44506863)
4. Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003; 103: 321-324 (Pubitemid 36638820)
5. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsades de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137: 501-504 (Pubitemid 35024621)
6. De Bels D, Staroukine M, Devriendt J. Torsades de pointes due to methadone. Ann Intern Med 2003; 139: E156.
7. Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, et al. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003; 92: 995-997 (Pubitemid 37214820)
8. Piguet V, Desmeules J, Ehret G, Stoller R, Dayer P. QT interval prolongation in patients on methadone with concomitant drugs. J Clin Psychopharmacol 2004; 24: 446-448 (Pubitemid 38944145)
9. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005; 29: 385-391 (Pubitemid 40602519)
10. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a crosssectional study. Addiction 2007; 102: 289-300. (Pubitemid 46096291)
11. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166: 1280-1287 (Pubitemid 43967579)
12. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95: 915-918 (Pubitemid 40386816)
13. Martell BA, Arnsten JH, Ray B, Gourevitch MN. The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med 2003; 139: 154-155 (Pubitemid 38129111)
14. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. Pharmacotherapy 2005; 25: 1523-1529
15. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105: 499-506. (Pubitemid 37186911)
16. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14: 747-753
17. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 2002; 303: 688-694
18. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37: 17-40.
19. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-2127 (Pubitemid 37430214)
20. Ferreira S, Crumb WJ Jr, Carlton CG, Clarkson CW. Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. J Pharmacol Exp Ther 2001; 299: 220-226 (Pubitemid 32905138)
21. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Pale thorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45.
22. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022
23. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002; 89: 1316-1319
24. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11: 44-49 (Pubitemid 40082210)